Small molecule compounds targeting miRNAs for cancer therapy
نویسندگان
چکیده
منابع مشابه
Small-molecule targeting of translation initiation for cancer therapy
Translation initiation plays a critical role in the regulation of cell growth and tumorigenesis. We report here that inhibiting translation initiation through induction of eIF2α phosphorylation by small-molecular-weight compounds restricts the availability of the eIF2.GTP.Met-tRNAi ternary complex and abrogates the proliferation of cancer cells in vitro and tumor growth in vivo. Restricting the...
متن کاملSmall molecule targeting miR-34a for cancer therapy
miR-34a functions as a tumor suppressor in many cancers. In a recent issue of Cancer Research, we describe a small molecule, Rubone, with strong anticancer activity. Rubone selectively restored miR-34a expression in hepatocellular carcinoma cells in which miR-34a was silenced. Restoration of miR-34a by Rubone represents a promising therapeutic approach against cancer.
متن کاملSmall Molecule Bax Agonists for Cancer Therapy
Bax, a central death regulator, is required at the decisional stage of apoptosis. We recently identified serine 184 (S184) of Bax as a critical functional switch controlling its proapoptotic activity. Here we used the structural pocket around S184 as a docking site to screen the NCI library of small molecules using the UCSF-DOCK programme suite. Three compounds, small-molecule Bax agonists SMBA...
متن کاملTargeting DDX3 with a small molecule inhibitor for lung cancer therapy
Lung cancer is the most common malignancy worldwide and is a focus for developing targeted therapies due to its refractory nature to current treatment. We identified a RNA helicase, DDX3, which is overexpressed in many cancer types including lung cancer and is associated with lower survival in lung cancer patients. We designed a first-in-class small molecule inhibitor, RK-33, which binds to DDX...
متن کاملPolymer-Based Prodrugs: Improving Tumor Targeting and the Solubility of Small Molecule Drugs in Cancer Therapy.
The majority of anticancer drugs have poor aqueous solubility, produce adverse effects in healthy tissue, and thus impose major limitations on both clinical efficacy and therapeutic safety of cancer chemotherapy. To help circumvent problems associated with solubility, most cancer drugs are now formulated with co-solubilizers. However, these agents often also introduce severe side effects, there...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Advanced Drug Delivery Reviews
سال: 2015
ISSN: 0169-409X
DOI: 10.1016/j.addr.2014.09.002